Devyser Diagnostics AB (publ) Interim report January - September 2026

Q3

Materially improved results

Quarter from July to September 2026

- Net sales amounted to SEK 59.7 million (56.4), corresponding to a 5.8 percent increase. Adjusted for exchange rate fluctuations, net sales increase by 5.7 percent.
- Gross profit amounted to SEK 49.5 million (42.3), which corresponds to a gross margin of 83.0 percent (75.0).
- Operating profit (EBIT) amounted to SEK 7.1 million (1.3).
- Profit/loss after tax totaled SEK 7.3 million (-2.8).
- Earnings per share before and after dilution amounted to SEK 0.43 (-0.17).
- Cash flow from operating activities stood at SEK 22.0 million (-0.5).

Important events during the quarter

Devyser reported weaker sales in the second quarter due to a distributor's inventory buildup

In July, Devyser reported that sales in the second quarter were weaker than expected, due to a significant inventory buildup at the company's largest distributor in 2025 and early 2026, which reduced the need for purchases during the period. The inventory buildup continued to negatively affect sales in the third quarter, and is also expected to have an impact in the fourth quarter. Sales to the distributor are expected to gradually normalize from 2027.

Devyser launched One Lambda Devyser Chimerism Plus

In mid-July, Devyser announced an expanded collaboration with Thermo Fisher Scientific through the launch of One Lambda Devyser Chimerism Plus, a next-generation solution for chimerism assays following stem cell transplants. The launch strengthens Devyser's product portfolio, and the product will reach the market through Thermo Fisher's global network.

Devyser signed its first reagent rental agreement

The agreement, signed in August with a laboratory in Italy, marks an important step towards increasing access to next-generation sequencing (NGS), by combining Illumina's instrument platform with Devyser's assay portfolio.

The agreement covers the installation of an Illumina MiSeq™ i100 System within the framework of a reagent rental model. The customer will implement a number of Devyser's assays within the agreement, and use Devyser's Amplicon Suite software to support data analysis and reporting.

The period from January to September 2026

- Net sales amounted to SEK 181.7 million (178.5), corresponding to a 1.8 percent increase. Adjusted for exchange rate fluctuations, net sales increased by 4.9 percent.
- Gross profit totaled SEK 145.8 million (144.7), corresponding to a gross margin of 80.2 percent (81.1).
- Operating profit (EBIT) amounted to SEK 10.2 million (-8.0).
- Profit/loss after tax totaled SEK 11.8 million (-22.0).
- Earnings per share before and after dilution amounted to SEK 0.70 (-1.33).
- Cash flow from operating activities stood at SEK 46.4 million (-3.5).

Torben Thölix was appointed as the new Chief Commercial Officer

At the end of August, Torben Thölix was appointed as the new CCO for Devyser's global commercial organization. Torben has more than 20 years of experience in international commercial leadership within life sciences and healthcare. Torben took up his post on October 1.

Important events after the end of the quarter

Doubling of test volume in new Italian tender

Devyser's Italian subsidiary won a tender from Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico in Milan, one of Italy's leading university hospitals, for the company's NGS test Devyser Thalassemia and its Amplicon Suite analysis software. The new three-year agreement is for double the test volume of the period covered by the previous agreement and has a total value of around SEK 5.7 million.

Expansion of the scope of Devyser's transplant test to include heart and lung transplant patients

In October, Devyser announced that the scope of One Lambda Devyser Accept cfDNA, the company's test for kidney transplant patient follow-up, has been expanded, and that the test can now also be used following heart and lung transplants. Laboratories can therefore use the same test solution for kidney, heart and lung transplant patient follow-up. The new test solution broadens the total market for the product, and is reaching customers through Thermo Fisher Scientific's global commercial network.

Performance measures	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Oct 2025 - Sep 2026	Jan - Dec 2025
Net sales, SEK million	59.7	56.4	181.7	178.5	253.7	250.5
Sales growth, %	5.8	15.7	1.8	16.9	4.5	15.5
Gross margin, %	83.0	75.0	80.2	81.1	80.0	80.6
Operating profit/loss (EBIT), SEK million[1]	7.1	1.3	10.2	-8.0	28.2	10.1
Operating margin (EBIT margin), %[1]	11.9	2.3	5.6	Neg	11.1	4.0
Profit/loss after tax, SEK million	7.3	-2.8	11.8	-22.0	25.4	-8.4
Cash flow from operating activities, SEK million[1]	22.0	-0.5	46.4	-3.5	58.1	8.2
Cash and cash equivalents, SEK million	88.7	84.9	88.7	84.9	88.7	77.5
Equity ratio, %	78.7	74.1	78.7	74.1	78.7	75.4
Return on equity, %	1.9	Neg	3.2	Neg	7.0	Neg

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1. See page 16 for definitions of the performance measures.

A word from the CEO

Our direct sales markets continued to grow in the third quarter. Over the period, we also took important steps to strengthen the business ahead of 2027. We broadened our product portfolio, launched a new chimerism assay together with Thermo Fisher Scientific, signed our first reagent rental agreement in collaboration with Illumina, and recruited a new Chief Commercial Officer. As we reported in July, our largest distributor's inventory adjustment continued to hold back sales. Underlying demand remains strong. It is also positive that we significantly improved our profitability compared with the previous year, over both the quarter and the period from January to September.

Continued growth in our direct sales markets

Net sales for the third quarter amounted to SEK 59.7 million (56.4). Direct sales increased by 6 percent, to SEK 45.1 million, and accounted for 75.5 percent of net sales. Sales to distributors amounted to SEK 14.6 million, which reflects our largest distributor's inventory adjustment. For the first nine months of the year, net sales amounted to SEK 181.7 million. Growth was driven by our NGS product launches, CFTR and Thalassemia being the main growth drivers in 2026. So far this year, our hereditary disease product sales in the US have more than doubled, led by CFTR, Thalassemia, Compact and HLA loss.

In Italy, after the end of the quarter, we won a renewed NGS tender worth around SEK 5.7 million. The agreement, with one of the country's leading university hospitals, doubles the test volume compared with the previous period, and is proof of continued strong demand for Devyser's products in one of our most important direct sales markets.

A question of timing, not demand

As we reported in July, our largest distributor is working to reduce the inventory that it previously built up. Despite this one-off correction, which means lower reported sales in 2026, underlying demand has developed strongly, and sales of our transplant products to end customers are continuing to grow. We still expect weaker sales to the distributor for the rest of 2026, after which there should be a return to more normal levels in 2027.

Significantly improved profitability and cash flow

The gross margin for the quarter amounted to 83.0 percent (75.0). Operating profit (EBIT) amounted to SEK 7.1 million (1.3), marking our sixth consecutive quarter with a positive operating result. We are very pleased with the improved profitability, both over the quarter and for the year to date. Cash flow from operating activities amounted to SEK 22.0 million (-0.5). Cash and cash equivalents amounted to SEK 88.7 million at the end of the quarter.

Two partnerships that are broadening our market presence

In July, we launched One Lambda Devyser Chimerism Plus together with Thermo Fisher Scientific. This next-generation chimerism assay for post-stem cell transplant follow-up is reaching laboratories through Thermo Fisher's global network. The launch strengthens our long-term strategic collaboration with Thermo Fisher while expanding our transplant portfolio and strengthening our market position.

The collaboration with Thermo Fisher was further developed in October when we broadened the applications for One Lambda Devyser Accept cfDNA, our NGS-based test for post-transplant follow-up. Expanding the scope from just kidney transplant patients to include heart and lung patients made the target group for the test much broader, while laboratories are able to use the same solution for different types of organ transplants, which has been requested by a number of customers. And this has a significant impact on patients. Some children who have undergone a heart transplant may need to undergo numerous biopsies during the first year alone. With IVDR certification for heart transplantation, our solution can help reduce the need for some of these invasive procedures, instead enabling follow-up monitoring through a simple blood test. Here as well, Thermo Fisher's global reach is giving us access to the laboratories that need the new test solution.

In August, we signed our first commercial reagent rental agreement with a laboratory in Italy in collaboration with Illumina. The model is based on replacing an initial capital investment with a multi-year commitment to purchase reagents, which provides us with recurring and more predictable revenue. We expect the agreement to serve as a reference for more reagent rental agreements in Europe, and several similar business opportunities are already in process.

Upcoming milestones

Both the FDA process and the MolDx application are progressing, and we remain committed to our goal of announcing a decision on MolDx before the end of the year. Preparations for commercialization and work on our channel strategy are underway. At the same time, we are continuing to further develop our clinical and regulatory evidence as we work towards our IVDR certifications.

> "Underlying demand remains strong, and we stand by our positive long-term view of the market ahead of 2027."

An enhanced management team

Torben Thölix took up his post as Chief Commercial Officer on October 1, and now leads our global commercial organization, the US being a particularly significant opportunity. During the quarter, Niklas Axelsson also assumed his duties as CFO, strengthening our finance organization.

Outlook

Demand remains strong in our direct sales markets and in other distributor markets. We are continuing to prioritize our core markets: the US and Western Europe. Our aim is to deliver profitable growth, and to grow faster than the underlying market.

We are approaching the last quarter of the year with a new Chief Commercial Officer in place, two partnerships that strengthen our market presence, and the goal of securing a decision on MolDx before the end of the year. I would like to thank all our employees, partners and shareholders for your continued trust.

Stockholm, November 3, 2026

Jan Wahlström, CEO



Group development, January to September 2026

Net sales

Net sales for the period from January to September 2026 amounted to SEK 181.7 million (178.5), corresponding to an increase of 1.8 percent. Adjusted for exchange rate fluctuations, sales increased by 4.9 percent.

Net sales for the third quarter of 2026 amounted to SEK 59.7 million (56.4), corresponding to an increase of 5.8 percent. Adjusted for exchange rate fluctuations, the increase was 5.7 percent.

The increase in the third quarter was primarily driven by increased sales to new and existing customers, but with a negative impact from decreased sales to the company's largest distributor compared with the same quarter of last year.

There are no major seasonal variations in the company's sales.

Gross profit

Gross profit for the period from January to September 2026 totaled SEK 145.8 million (144.7). Gross profit for the third quarter totaled SEK 49.5 million (42.3).

The gross margin for the period from January to September 2026 amounted to 80.2 percent, compared with 81.1 percent for the same period of the previous year.

For the third quarter, the gross margin amounted to 83 percent, compared with 75 percent for the same quarter of last year.

Cost of goods sold includes the direct manufacturing costs of products sold and the amortization of capitalized development expenses.

The amortization of capitalized development expenses amounted to SEK 6.7 million (4.1) for the period from January to September, and to SEK 2.3 million (1.4) for the third quarter of 2026.

Operating expenses

Operating expenses for the period from January to September 2026 amounted to SEK 136.5 million (152.3), and for the third quarter to SEK 43.0 million (40.9). The lower expenses for the period from January to September 2026 are mainly due to increased cost efficiency within the organization. The increased expenses for the quarter compared with the previous year are mainly due to when expenses occurred during the year.

Total research and development costs during the period from January to September 2026 amounted to SEK 52.8 million (74.5), of which SEK 37.6 million (59.0) was capitalized and SEK 15.3 million (15.5) was expensed. During the third quarter of 2026, the costs amounted to SEK 15.5 million (20.0), of which SEK 11.8 million (16.6) was capitalized and SEK 3.7 million (3.5) was expensed.

The expensed research and development costs mainly comprise employee and consultant-related costs attributable to the R&D department's non-capitalizable project phases. The capitalized expenses include costs for development projects related to products not yet completed.

For the period from January to September 2026, other operating income and expenses, mainly consisting of exchange gains/losses on current assets and current liabilities, amounted to SEK 1.0 million (-0.5) net, and amounted to SEK 0.6 million (-0.1) net for the third quarter. See Note 1.

Operating profit/loss


Operating profit/loss for the period from January to September 2026 totaled SEK 10.2 million (-8.0). For the third quarter, operating profit/loss came to SEK 7.1 million (1.3). See Note 1. The improvement in operating profit/loss for the first three quarters of 2026 is primarily due to the cost-saving measures implemented, but it was also negatively impacted by lower net sales in the second quarter.

Net financial items

Net financial items for the period from January to September 2026 totaled SEK 4.5 million (-10.7). For the third quarter, net financial items stood at SEK 1.7 million (-1.1). The net financial items consist mainly of currency translation differences related to long-term intra-Group loans in foreign currency. See Note 1.

Profit/loss

Profit/loss before tax for the period from January to September 2026 was SEK 14.7 million (-18.7), and profit/loss after tax was SEK 11.8 million (-22.0). For the third quarter, profit/loss before tax was SEK 8.7 million (0.2) and profit/loss after tax was SEK 7.3 million (-2.8). At year-end 2025, the parent company had tax loss carryforwards amounting to SEK 254.5 million. See Note 4.



Sales by region, SEK million	Jul - Sep 2026	Jul - Sep 2025	Change, %	Jan - Sep 2026	Jan - Sep 2025	Change, %	Oct 2025 - Sep 2026	Jan - Dec 2025
EMEA	50.3	47.7	5.3	151.3	144.8	4.5	216.0	209.4
Asia-Pacific	2.3	1.7	33.0	6.1	5.2	16.7	8.3	7.4
North and South America	7.1	6.9	2.6	24.3	28.5	-14.9	29.4	33.6
Total	**59.7**	**56.4**	**5.8**	**181.7**	**178.5**	**1.8**	**253.7**	**250.5**

Sales by sales channel, SEK million	Jul - Sep 2026	Jul - Sep 2025	Change, %	Jan - Sep 2026	Jan - Sep 2025	Change, %	Oct 2025 - Sep 2026	Jan - Dec 2025
Direct sales	45.1	42.5	6.0	138.4	124.7	11.0	182.2	168.5
Distributor sales	14.6	13.9	5.3	43.3	53.9	-19.7	71.4	82.0
Total	**59.7**	**56.4**	**5.8**	**181.7**	**178.5**	**1.8**	**253.7**	**250.5**

During the fourth quarter of 2025, certain reclassifications were made to the allocation of sales by region and sales channel. For improved comparability, the amounts presented in the tables above have been restated based on the current classification.

Cash flow and cash position

For the period from January to September 2026, the cash flow from operating activities after changes in working capital was SEK 46.4 million (-3.5). For the third quarter of 2026, the cash flow from operating activities amounted to SEK 22.0 million (-0.5). During the period, five new issues of a total of 236,149 shares were completed; one when CyberGene AB was acquired, and four in connection with the exercising of employee stock options issued to employees. The issues in connection with the exercising of employee stock options raised SEK 9.9 million for the company. Cash and cash equivalents as of September 30, 2026 amounted to SEK 88.7 million (84.9).

Investments

Total net investments during the period from January to September 2026 amounted to SEK 37.7 million (55.1), including capitalized development expenses of SEK 37.6 million (52.7). For the period from July to September, total net investments amounted to SEK 12.0 million (17.4), including capitalized development expenses of SEK 11.8 million (16.6). The Group has no investment commitments.

Assets

As of September 30, 2026, intangible non-current assets amounted to SEK 201.8 million (147.7). Intangible non-current assets consist of capitalized development expenses for Devyser's products, other intangible assets and consolidated goodwill.

During the period from January to September 2026, SEK 30.4 million (39.6) of the capitalized development expenses were apportioned to the Research and Development function, SEK 5.7 million (12.6) to the Sales function, and SEK 1.3 million (0.5) to other functions. Capitalized development expenses are amortized on a straight-line basis over their estimated useful lives, which vary from four to ten years.

The amortization of capitalized development expenses attributable to the products developed by Devyser is recognized in the Group cost of goods sold and in the Parent Company's research and development costs.

Equity and liabilities

As of September 30, 2026, the Group's equity amounted to SEK 389.4 million (341.0) and the equity ratio was 78.7 percent (74.1).

As of September 30, 2026, interest-bearing liabilities amounted to SEK 44.0 million (51.5). Interest-bearing liabilities consist mainly of lease liabilities attributable to leases. Current non-interest-bearing liabilities totaled SEK 51.7 million (61.2).

Performance measures by quarter	Jul - Sep 2026	Apr - Jun 2026	Jan - Mar 2026	Oct - Dec 2025	Jul - Sep 2025	Apr - Jun 2025	Jan - Mar 2025
Net sales, SEK million	59.7	60.2	61.8	72.0	56.4	67.4	54.8
Gross profit, SEK million	49.5	45.8	50.5	57.2	42.3	56.8	45.6
Gross margin, %	83.0	76.0	81.6	79.5	75.0	84.2	83.4
EBITDA, SEK million[1]	14.7	8.1	10.1	25.0	8.1	12.2	-8.1
EBITDA margin, %[1]	24.6	13.4	16.3	34.7	14.4	18.1	Neg
Operating profit/loss (EBIT), SEK million[1]	7.1	0.5	2.6	18.0	1.3	5.5	-14.8
Operating margin (EBIT margin), %[1]	11.9	0.8	4.2	25.1	2.3	8.1	Neg
Profit/loss after tax, SEK million	7.3	1.6	2.9	13.6	-2.8	1.3	-20.5
Cash flow from operating activities, SEK million[1]	22.0	12.3	12.1	11.7	-0.5	2.6	-5.6
Average no. of employees	111	110	110	110	108	114	120

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
See page 16 for definitions of the performance measures.

Parent Company

Devyser Diagnostics AB (publ), Corporate Registration Number 556669-7834, is a Swedish limited company domiciled in Stockholm. The address of its head office is Bränningevägen 12, 120 54 Årsta, Sweden. Devyser Diagnostics AB has been listed on the Nasdaq First North Premier Growth Market since December 2021.

Receivables and liabilities in respect of Group companies primarily consist of amounts owed by the Swedish subsidiary Devyser AB and the Italian subsidiary Devyser Italia S.r.l. The Parent Company's risks and uncertainties indirectly coincide with those of the Group.

Important events in the Parent Company

The improved result for the Parent Company compared with the previous year is mainly due to increased cost efficiency within the organization.

During the period from January to September 2026, five new issues of a total of 236,149 shares were completed; one when CyberGene AB was acquired, and four in connection with the exercising of employee stock options issued to employees. The issues in connection with the exercising of employee stock options raised SEK 9.9 million for the company.

Employees

From January to September 2026, the average number of employees in the Group was 110 (115), of whom 2 (1) were in the Parent Company. The average number broken down by country was 76 (77) in Sweden, 16 (16) in Italy, 6 (11) in the United States, 3 (3) in Germany, 3 (3) in Belgium, 2 (2) in the United Kingdom, 2 (2) in Spain and 2 (2) in France. The average number of women employed by the Group was 68 (68) and the average number of men was 42 (48).

Market

Devyser sells genetic testing products to laboratories in more than 65 countries. The products include reagent kits and the related software. Sales are made primarily to routine diagnostic laboratories, partly through our own sales teams in selected markets and partly through distributors.

The products are used for advanced DNA analysis services for clinical genetics and post-transplantation laboratories for the diagnosis of a wide range of genetic diseases and transplant patient follow-up.

The market for the company's products is large, and is estimated by an external market survey to total EUR 5.6 billion in 2026.

Related-party transactions

See Notes 2 and 3 for a description of the incentive programs and related-party transactions.

Significant risks and uncertainties

The Group's activities are associated with a number of risks and uncertainties.

While Russia's invasion of Ukraine and the uncertain situation in the Middle East have no direct impact on Devyser, geopolitical uncertainty and the impact on global transportation may affect both the price of purchased goods and the company's ability to deliver to its customers.

The continued uncertainty regarding global trade barriers and the increased risk of a trade war could affect Devyser if its suppliers raise their prices. Tariffs on imports into the US are expected to have a limited impact on the company's costs and revenues.

A possible recession driven by the global turmoil could affect future revenues.

Devyser's sales are mainly in Euros and US dollars, meaning that the company is exposed to exchange rate fluctuations.

For more information, a detailed description of the company's risk exposure can be found in the 2025 Annual Report, pages 43-44, and in Note 13, pages 81-89. No changes are considered to have occurred since the Annual Report was published other than those described above.

The share and shareholders

As of September 30, 2026, Devyser Diagnostics AB had a total of 16,889,806 (16,653,657) shares and voting rights.

On the submission date of this report, the company had four outstanding incentive programs for employees and key personnel.

The existing and new incentive programs may currently increase the number of shares by 368,653 (see Note 2).

The largest shareholders as of September 30, 2026 were:

Owner	Number of shares	Ownership, %
Rutger Arnhult via company	4,107,086	24.3
Nordnet Pensionsförsäkringar	1,139,205	6.7
Handelsbanken Fonder	1,072,495	6.3
Premier Miton Investors	977,326	5.8
Deka Investments	864,561	5.1
Fourth Swedish National Pension Fund	759,821	4.5
Protean Funds Scandinavia	719,365	4.3
Åsa Riisberg via company	664,294	3.9
Swedbank Robur	399,159	2.4
HealthInvest Partners	370,264	2.2
Other shareholders, around 2,100	5,816,230	34.4
Total	**16,889,806**	**100.0**

Source: Monitor

Auditors' review

This report has been reviewed by the company's auditors.

The Board of Directors and CEO certify that the interim report provides a true and fair overview of the operations, financial position and earnings of the Group and the Parent Company and describes the significant risks and uncertainties faced by the Parent Company and the companies included in the Group.

Stockholm, November 3, 2026
Devyser Diagnostics AB (publ)

Mia Arnhult
Chair of the Board

Fredrik Dahl
Board member

Olof Ericsson
Board member

Thomas Eklund
Board member

Pia Gideon
Board member

Jan Wahlström
Chief Executive Officer

Consolidated income statement

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Oct 2025 - Sep 2026	Jan - Dec 2025
Net sales	59.7	56.4	181.7	178.5	253.7	250.5
Cost of goods sold	-10.1	-14.1	-35.9	-33.8	-50.7	-48.6
Gross profit	**49.5**	**42.3**	**145.8**	**144.7**	**203.0**	**201.9**
Other operating income[1]	1.2	-1.8	2.9	2.6	3.6	3.3
Selling expenses[2]	-23.6	-26.2	-78.4	-93.0	-102.6	-117.3
Administrative expenses	-15.7	-11.2	-42.9	-43.7	-55.2	-56.0
Research and development costs	-3.7	-3.5	-15.3	-15.5	-17.7	-18.0
Other operating expenses[1]	-0.6	1.7	-1.9	-3.1	-2.8	-3.9
Operating profit/loss[1]	**7.1**	**1.3**	**10.2**	**-8.0**	**28.2**	**10.1**
Financial income[1]	2.3	0.1	6.5	0.8	6.6	0.9
Financial expenses[1]	-0.6	-1.2	-2.0	-11.5	-4.1	-13.6
Net financial items[1]	1.7	-1.1	4.5	-10.7	2.5	-12.7
Profit/loss before tax	**8.7**	**0.2**	**14.7**	**-18.7**	**30.8**	**-2.6**
Tax[3]	-1.4	-3.0	-2.9	-3.4	-5.4	-5.8
Profit/loss for the period	**7.3**	**-2.8**	**11.8**	**-22.0**	**25.4**	**-8.4**
Earnings per share before dilution, SEK	0.43	-0.17	0.70	-1.33	1.52	-0.51
Diluted earnings per share, SEK	0.43	-0.17	0.70	-1.33	1.52	-0.51
Average number of shares before dilution	16,889,806	16,607,170	16,783,839	16,572,135	16,751,026	16,592,683
Average number of shares after dilution	16,889,806	16,701,283	16,783,839	16,623,375	16,751,026	16,663,556

Consolidated statement of comprehensive income

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Oct 2025 - Sep 2026	Jan - Dec 2025
Profit/loss for the period	**7.3**	**-2.8**	**11.8**	**-22.0**	**25.4**	**-8.4**
Other comprehensive income for the period:						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss						
Currency translation differences	0.4	-0.1	-0.0	2.9	-0.9	2.0
Other comprehensive income for the period	**0.4**	**-0.1**	**-0.0**	**2.9**	**-0.9**	**2.0**
Total comprehensive income for the period	**7.8**	**-2.9**	**11.8**	**-19.2**	**24.5**	**-6.4**

Since there are no minority interests in the Group (no non-controlling interests), all earnings are wholly attributable to the owners of the Parent Company.

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
2) See Note 5.
3) See Note 4.

Consolidated statement of financial position

SEK million	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Goodwill	15.4	6.7	6.6
Capitalized development expenses	178.8	131.8	145.2
Other intangible assets	7.6	9.2	8.7
Equipment, tools and plant	27.7	32.7	30.8
Right-of-use assets	43.8	51.7	52.1
Deferred tax assets[1]	19.8	21.1	21.1
Other non-current receivables	1.0	1.0	1.0
Total non-current assets	**294.2**	**254.2**	**265.4**
Current assets			
Inventories	43.3	37.8	37.0
Trade receivables	50.0	51.4	56.8
Current tax assets	6.1	4.9	7.2
Other receivables	1.7	2.8	3.0
Prepaid expenses and accrued income	11.2	23.8	22.7
Cash and cash equivalents	88.7	84.9	77.5
Total current assets	**200.8**	**205.7**	**204.3**
TOTAL ASSETS	**495.0**	**459.9**	**469.7**
EQUITY AND LIABILITIES			
EQUITY			
Share capital	1.0	1.0	1.0
Share premium	567.6	545.7	545.7
Translation reserve	2.5	3.4	2.6
Retained earnings, including profit/loss for the period	-181.6	-209.2	-194.9
TOTAL EQUITY	**389.4**	**341.0**	**354.3**
LIABILITIES			
Non-current liabilities			
Borrowings	0.2	0.3	0.3
Lease liabilities	30.0	38.4	37.5
Deferred tax liabilities	0.0	0.1	0.1
Provisions[2]	7.2	4.3	4.6
Other non-current liabilities	2.5	1.9	2.0
Total non-current liabilities	**40.0**	**45.0**	**44.4**
Current liabilities			
Borrowings	-	0.1	-
Lease liabilities	13.8	12.7	14.1
Trade payables	15.1	10.6	17.9
Current tax liabilities	0.4	0.6	1.3
Other liabilities	13.0	15.4	15.1
Accrued expenses and deferred income	23.3	34.6	22.5
Provisions[2]	-	-	-
Total current liabilities	**65.5**	**74.0**	**70.9**
TOTAL EQUITY AND LIABILITIES	**495.0**	**459.9**	**469.7**

1) See Note 4.
2) See Note 5.

Consolidated statement of changes in equity

SEK million	Share capital	Share premium	Translation reserve	Retained earnings, including profit/loss for the period	Total equity
Opening equity, Jan 1, 2025	**1.0**	**536.5**	**0.6**	**-189.0**	**349.0**
Comprehensive income					
Profit/loss for the period	-	-	-	-22.0	-22.0
Other comprehensive income for the period	-	-	2.9	-	2.9
Total comprehensive income	-	-	2.9	-22.0	-19.2
Shareholder transactions					
New share issues	0.0	9.4	-	-	9.4
Issue expenses	-	-0.1	-	-	-0.1
Employee stock options	-	-	-	1.8	1.8
Closing equity, Sep 30, 2025	**1.0**	**545.7**	**3.4**	**-209.2**	**341.0**
Comprehensive income					
Profit/loss for the period	-	-	-	13.6	13.6
Other comprehensive income for the period	-	-	-0.9	-	-0.9
Total comprehensive income	-	-	-0.9	13.6	12.7
Shareholder transactions					
New share issues	-	0.0	-	-	0.0
Issue expenses	-	-0.0	-	-	-0.0
Employee stock options[1]	-	-	-	0.7	0.7
Closing equity, Dec 31, 2025	**1.0**	**545.7**	**2.6**	**-194.9**	**354.3**
Opening equity, Jan 1, 2026	**1.0**	**545.7**	**2.6**	**-194.9**	**354.3**
Comprehensive income					
Profit/loss for the period	-	-	-	11.8	11.8
Other comprehensive income for the period	-	-	-0.0	-	-0.0
Total comprehensive income	-	-	-0.0	11.8	11.8
Shareholder transactions					
New share issues	0.0	22.2	-	-	22.2
Issue expenses	-	-0.3	-	-	-0.3
Employee stock options[1]	-	-	-	1.5	1.5
Closing equity, Sep 30, 2026	**1.0**	**567.6**	**2.5**	**-181.6**	**389.4**

1) The item employee stock options includes net share-based payments and the related deferred tax.

Consolidated cash flow statement

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Oct 2025 - Sep 2026	Jan - Dec 2025
Cash flow from operating activities						
Operating profit/loss[1],[2]	7.1	1.3	10.2	-8.0	28.2	10.1
Adjustment for non-cash items						
- Depreciation, amortization and impairment	7.6	6.8	22.6	20.1	29.6	27.1
- Other non-cash items	1.6	-0.7	4.8	1.6	5.8	2.7
Interest received	0.1	0.0	0.2	0.1	1.1	0.9
Interest paid	-0.6	-0.7	-2.0	-2.3	-2.7	-3.0
Income tax paid	-2.2	-3.5	-2.1	-4.4	-6.1	-8.4
Cash flow from operating activities before changes in working capital[1]	**13.6**	**3.2**	**33.7**	**7.1**	**55.9**	**29.3**
Cash flow from changes in working capital						
Increase (-)/Decrease (+) in inventories	1.2	1.4	-5.8	-8.0	-5.1	-7.3
Increase (-)/Decrease (+) in operating receivables	12.4	-4.7	23.6	-6.6	17.7	-12.5
Increase (+)/Decrease (-) in operating payables	-5.1	-0.4	-5.1	3.9	-10.4	-1.4
Cash flow from operating activities[1]	**22.0**	**-0.5**	**46.4**	**-3.5**	**58.1**	**8.2**
Cash flow from investing activities						
Investments in intangible non-current assets	-11.8	-16.6	-37.6	-53.2	-53.2	-68.7
Investments in property, plant and equipment	-0.1	-0.8	-1.4	-1.5	-1.5	-1.5
Acquisition of subsidiaries	0.0	-	1.4	-	1.4	-
Change in financial assets	-	0.0	-	-0.5	0.0	-0.5
Cash flow from investing activities	**-12.0**	**-17.4**	**-37.7**	**-55.1**	**-53.2**	**-70.7**
Cash flow from financing activities						
New share issues	0.0	5.8	9.9	9.4	9.9	9.4
Issue expenses	-0.1	-0.0	-0.3	-0.1	-0.3	-0.2
Repayments of borrowings	-0.0	-0.0	-0.1	-0.1	-0.1	-0.1
Repayments of lease liabilities	-3.1	-3.1	-9.2	-8.9	-12.3	-12.0
Cash flow from financing activities	**-3.1**	**2.7**	**0.4**	**0.3**	**-2.8**	**-2.8**
Cash flow for the period[1]	**6.9**	**-15.2**	**9.1**	**-58.4**	2.2	-65.4
Cash and cash equivalents at the beginning of the period	81.0	100.4	77.5	144.5	84.9	144.5
Exchange gains/losses on cash and cash equivalents[1]	0.8	-0.3	2.0	-1.2	1.6	-1.7
Cash and cash equivalents at the end of the period	**88.7**	**84.9**	**88.7**	**84.9**	**88.7**	**77.5**

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.
2) See Note 5.

Parent Company income statement

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Jan - Dec 2025
Net sales	14.1	8.1	39.1	31.0	49.8
Cost of goods sold	-0.0	-	-0.4	-0.2	-0.4
Gross profit	**14.1**	**8.1**	**38.7**	**30.9**	**49.4**
Other operating income	0.0	0.0	0.1	0.0	0.0
Administrative expenses	-5.5	-4.5	-16.5	-20.0	-24.6
Research and development costs	-2.1	-1.4	-6.3	-4.0	-5.4
Other operating expenses	-0.0	-0.0	-0.0	-0.0	-0.0
Operating profit/loss	**6.6**	**2.2**	**16.0**	**6.9**	**19.3**
Net interest and similar items	0.0	1.6	0.1	2.2	2.3
Profit/loss from financial items	**0.0**	**1.6**	**0.1**	**2.2**	**2.3**
Profit/loss after financial items	**6.6**	**3.8**	**16.2**	9.1	21.6
Appropriations	-	-	-	-	-32.6
Profit/loss before tax	**6.6**	**3.8**	**16.2**	**9.1**	**-10.9**
Tax[1]	0.0	-1.3	-0.1	-1.3	-1.3
Profit/loss for the period	**6.6**	**2.5**	**16.1**	**7.8**	**-12.2**

Parent Company statement of comprehensive income

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Jan - Dec 2025
Profit/loss for the period and Total comprehensive income for the period	**6.6**	**2.5**	**16.1**	**7.8**	**-12.2**

As there are no items of other comprehensive income, the Parent Company's earnings are the same as the comprehensive income.

1) See Note 4.

Parent Company balance sheet

SEK million	Sep 30, 2026	Sep 30, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Intangible assets			
Capitalized development expenses	137.7	109.9	119.0
Total intangible assets	**137.7**	**109.9**	**119.0**
Financial non-current assets			
Investments in Group companies	171.4	157.4	157.8
Deferred tax assets[1]	19.1	19.2	19.2
Total financial non-current assets	**190.5**	**176.6**	**177.0**
Total non-current assets	**328.2**	**286.5**	**296.0**
Current assets			
Amounts owed by Group companies	56.4	33.3	20.4
Current tax assets	1.0	1.0	0.5
Other receivables	0.0	0.8	-
Prepaid expenses and accrued income	2.0	1.6	0.5
Cash in hand and at bank	5.8	48.6	33.7
Total current assets	**65.1**	**85.2**	**55.1**
TOTAL ASSETS	**393.2**	**371.7**	**351.1**
EQUITY AND LIABILITIES			
EQUITY			
Share capital	1.0	1.0	1.0
Statutory reserve	3.7	3.7	3.7
Reserve for development expenses	137.7	110.2	119.0
Total restricted equity	**142.4**	**114.9**	**123.7**
Share premium reserve	563.8	542.0	542.0
Retained earnings	-337.3	-300.5	-308.6
Profit/loss for the period	16.1	7.8	-12.2
Total non-restricted equity	**242.7**	**249.4**	**221.1**
TOTAL EQUITY	**385.0**	**364.2**	**344.9**
LIABILITIES			
Current liabilities			
Trade payables	0.5	1.0	0.9
Amounts owed to Group companies	0.9	-	0.0
Other liabilities	4.3	3.3	3.6
Accrued expenses and deferred income	2.4	3.2	1.7
Total current liabilities	**8.2**	**7.4**	**6.2**
TOTAL EQUITY AND LIABILITIES	**393.2**	**371.7**	**351.1**

1) See Note 4.

Changes in the Parent Company's equity

SEK million	Share capital	Reserve for development expenses	Reserves	Share premium reserve	Retained earnings	Profit/loss for the period	Total equity
Opening equity, Jan 1, 2025	**1.0**	**70.8**	**3.7**	**532.7**	**-206.2**	**-56.3**	**345.7**
Profit/loss for the period	-	-	-	-	-	7.8	7.8
Appropriation of earnings	-	-	-	-	-56.3	56.3	-
Capitalization of development expenses	-	39.4	-	-	-39.4	-	-
New share issues	0.0	-	-	9.4	-	-	9.4
Issue expenses	-	-	-	-0.1	-	-	-0.1
Employee stock options	-	-	-	-	1.5	-	1.5
Closing equity, Sep 30, 2025	**1.0**	**110.2**	**3.7**	**542.0**	**-300.5**	**7.8**	**364.2**
Profit/loss for the period	-	-	-	-	-	-20.0	-20.0
Capitalization of development expenses	-	8.8	-	-	-8.8	-	-
New share issues	-	-	-	0.0	-	-	0.0
Employee stock options	-	-	-	-	0.7	-	0.7
Closing equity, Dec 31, 2025	**1.0**	**119.0**	**3.7**	**542.0**	**-308.6**	**-12.2**	**344.9**
Opening equity, Jan 1, 2026	**1.0**	**119.0**	**3.7**	**542.0**	**-308.6**	**-12.2**	**344.9**
Profit/loss for the period	-	-	-	-	-	16.1	16.1
Appropriation of earnings	-	-	-	-	-12.2	12.2	-
Capitalization of development expenses	-	18.6	-	-	-18.6	-	-
New share issues	0.0	-	-	22.2	-	-	22.2
Issue expenses	-	-	-	-0.3	-	-	-0.3
Employee stock options[1]	-	-	-	-	2.2	-	2.2
Closing equity, Sep 30, 2026	**1.0**	**137.7**	**3.7**	**563.8**	**-337.3**	**16.1**	**385.0**

1) The item employee stock options includes net share-based payments and the related deferred tax.

Parent Company cash flow

SEK million	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Jan - Dec 2025
Cash flow from operating activities					
Operating profit/loss	6.6	2.2	16.0	6.9	19.3
Adjustments for non-cash items					
- Depreciation, amortization and impairment	2.1	1.4	6.3	4.0	5.4
- Other non-cash items	0.3	1.2	0.9	1.8	2.1
Interest received	0.0	0.0	0.0	0.0	0.8
Interest paid	0.0	-0.0	-0.0	-0.0	-0.0
Tax paid	-0.1	-0.1	-0.4	-0.4	-
Cash flow from operating activities before changes in working capital	**8.8**	**4.6**	**22.7**	**12.3**	**27.7**
Cash flow from changes in working capital					
Increase (-)/Decrease (+) in operating receivables	-3.9	-13.6	-40.3	-32.4	-51.0
Increase (+)/Decrease (-) in operating payables	-7.0	-0.2	5.0	-10.1	-11.3
Cash flow from operating activities	**-2.0**	**-9.2**	**-12.6**	**-30.2**	**-34.5**
Cash flow from investing activities					
Investments in intangible non-current assets	-7.1	-11.6	-24.9	-43.4	-54.0
Cash flow from investing activities	**-7.1**	**-11.6**	**-24.9**	**-43.4**	**-54.0**
Cash flow from financing activities					
New share issues	0.0	5.8	9.9	9.4	9.4
Issue expenses	-0.1	-0.0	-0.3	-0.1	-0.2
Cash flow from financing activities	**-0.1**	**5.7**	**9.7**	**9.3**	**9.2**
Cash flow for the period	**-9.2**	**-15.1**	**-27.9**	**-64.4**	**-79.3**
Cash and cash equivalents at the beginning of the period	15.0	63.7	33.7	113.0	113.0
Cash and cash equivalents at the end of the period	**5.8**	**48.6**	**5.8**	**48.6**	**33.7**

Notes

Note 1 Accounting policies

The interim report for the Devyser Group has been prepared in accordance with IFRS (International Financial Reporting Standards) as adopted by the EU. The Swedish Annual Accounts Act and RFR 1, Supplementary Accounting Rules for Groups, have also been applied.

The interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company applies the Swedish Annual Accounts Act and RFR 2, Accounting for Legal Entities. Under RFR 2, the Parent Company is required to apply the same accounting policies as the Group, which means that IFRS should be applied as far as possible within the framework of the Swedish Annual Accounts Act, the Swedish Pension Obligations Protection Act and tax considerations.

New or amended IFRS standards and other IFRIC interpretations came into effect on January 1, 2026. None of the new standards had any impact on the Group's or Parent Company's financial statements at September 30, 2026.

All amounts are reported in millions of kronor (SEK million) unless otherwise stated. Figures in brackets refer to the previous year. The figures in tables and calculations may be rounded, meaning that the total amounts shown may not always be the exact sum of the rounded amounts.

For more information about the accounting policies, refer to the 2025 Annual Report.

Reclassification of currency translation differences related to long-term intra-Group loans

From April 1, 2025, Devyser has classified currency translation differences related to long-term intra-Group loans denominated in foreign currencies as financial income/expenses. These items were previously reported under other operating income/expenses. The aim is to ensure a more accurate presentation of the operating profit/loss and to better reflect the nature of the currency translation differences. Comparative figures have been restated. See the tables on page 15.

Segment reporting

Devyser applies IFRS 8 Operating segments. Devyser's activities are currently focused on development and sales within a niche and uniform category of goods of a similar nature in the product area of diagnostic reagents, and only one segment is therefore reported, which is fully reflected in the Group's financial statements. All of its development activities are centered on the same common base product. The Group's strategic steering committee and highest decision-makers, consisting of the CEO and a number of other senior executives who together form the senior management, evaluate the Group's activities as a whole based on products and product development. Sales are monitored by geographic region, currently Europe, the Middle East and Africa (EMEA), Asia-Pacific, North and South America and other regions. Refer to the table on page 4.

Note 2 Incentive programs

Devyser has four outstanding incentive programs for employees and key personnel.

2023/2027 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 101.71 per share until June 2027. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of September 30, 2026, a total of 79,768 options had been granted and not exercised. Three members of the senior management together hold a total of 70,000 employee stock options.

2024/2028 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 136.48 per share until June 2028. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of September 30, 2026, a total of 127,085 options had been granted and not exercised. Five members of the senior management together hold a total of 83,000 employee stock options.

2025/2029 employee stock option plan

The total plan comprises 200,000 employee stock options, plus 62,840 options for the hedging of social security contributions. The options are granted free of charge. Each option entitles its holder to subscribe for one new share at SEK 186.24 per share until September 2029. The options are vested at a rate of one-third annually starting from the grant date, provided that the holder remains an employee.

As of September 30, 2026, a total of 157,800 options had been granted and not exercised. CEO Jan Wahlström holds 60,000 options. Five members of the senior management together hold a total of 50,000 employee stock options.

Long-term performance-based compensation plan 2026/2029

At the Annual General Meeting in May, a resolution was passed to introduce a new long-term performance-based compensation plan. The total plan comprises 75,000 stock options with underlying warrants, plus 23,565 warrants for the hedging of social security contributions. The stock options will be granted free of charge and vest over a period of 3 years from the grant date, following a performance review, provided that the holder remains an employee. The performance conditions will have three components: the meeting of sales growth targets, the meeting of profitability targets, and the meeting of the target number of tests administered to patients, during the fiscal years 2026, 2027, and 2028, and will be evaluated annually by the Board of Directors. Shares will be granted in 2029 after the end of the vesting period, provided that the conditions have been met.

As of September 30, 2026, a total of 27,200 stock options had been granted and not exercised. Five members of the senior management together hold a total of 9,000 stock options.

Note 3 Related-party transactions

Related-party transactions arise in the normal course of business and are carried out at arm's length and market prices. No related-party transactions took place during the period other than customary transactions between Group companies and the remuneration of management and the Board.

See Note 2 on incentive programs.

Note 4 Deferred tax

Within the Group, deferred tax is mainly recognized for accumulated losses, leases and share-based payments for which there are temporary differences that are grounds for the recognition of deferred tax.

The tax effects of loss carryforwards are taken into account only to the extent that there are convincing factors that suggest that these may be utilized in the foreseeable future. There are no time limits on any of the losses.

At year-end 2025, the Parent Company had unused tax loss carryforwards of SEK 254.5 million (241.0), corresponding to deferred tax assets of SEK 52.4 million (49.6). After valuation, SEK 19.1 million (19.1) is recognized in deferred tax assets in the balance sheet.

Note 5 Provision due to retroactive payback levy

The total provision recognized for the Italian Ministry of Health in connection with the payback levy for the years 2019-2025 amounted to SEK 4.6 million as of December 31, 2025. In the first three quarters of 2026, an additional SEK 2.3 million (0.5) was recognized. For detailed information about the provision, see Note 20 on page 92 of the 2025 Annual Report.

Note 6 Acquisition of CyberGene AB

On February 11, 2026, Devyser entered into an agreement to acquire 100 percent of the shares in CyberGene AB, a Swedish company belonging to the Level Bio AB (publ) Group. On April 1, 2026, the acquisition was completed and closing took place. The acquisition will strengthen Devyser's customer offering in the aneuploidy segment, and is expected to have a positive impact on Devyser's gross profit and gross margin.

At the time of closing, new consideration shares were issued to the seller, Level Bio AB (publ). The acquisition price was SEK 12.2 million. The directed share issue consisted of 124,363 shares, corresponding to a dilutive effect of 0.74 percent. The subscription price amounted to SEK 98.29 per share.

CyberGene AB, corp. reg. No 556504-5019, has been consolidated since April 1, 2026. The fair value of the net assets acquired totals SEK 3.7 million, and the calculated goodwill totals SEK 8.5 million. The cash acquired amounts to SEK 1.4 million. CyberGene AB's sales in 2025 amounted to SEK 5.3 million, with a reported EBIT of SEK 1.3 million. CyberGene AB develops and markets products in the aneuploidy and male infertility fields.

Since its consolidation, CyberGene has contributed SEK 2 million to Group revenue and had a SEK 0.9 million impact on earnings. If CyberGene had been consolidated from January 1, it would have had a positive impact on Group revenue of SEK 1.7 million, and a positive impact on earnings of SEK 0.4 million.

Reclassification of currency translation differences related to long-term intra-Group loans

	Apr - Jun 2025			Jan - Mar 2025		
SEK million	Recognized before reclassification	Restated amount	Recognized after reclassification	Recognized before reclassification	Restated amount	Recognized after reclassification
Consolidated income statement						
Operating profit/loss	5.5	-	5.5	-20.5	5.7	-14.8
Net financial items	-3.5	-	-3.5	-0.4	-5.7	-6.1
Consolidated cash flow statement						
Operating profit/loss	5.5	-	5.5	-20.5	5.7	-14.8
Cash flow from operating activities before changes in working capital	10.8	0.3	11.1	-12.9	5.7	-7.2
Cash flow from operating activities	2.3	0.3	2.6	-11.4	5.7	-5.6
Cash flow for the period	-14.8	0.3	-14.5	-34.4	5.7	-28.7
Exchange gains/losses on cash and cash equivalents	1.1	-0.3	0.8	4.0	-5.7	-1.7

Use of non-IFRS performance measures

The Devyser Group prepares its consolidated financial statements in accordance with IFRS. Only a few performance measures are defined in the IFRS standards. Devyser applies the Guidelines on Alternative Performance Measures (APMs) issued by the European Securities and Markets Authority (ESMA). To support the assessment of the Group's performance made by senior management and other stakeholders, Devyser uses some non-IFRS performance measures. Senior management believes that these measures make it easier to evaluate the performance of the Group.

Definitions of non-IFRS performance measures that are not provided elsewhere in this report are presented in the following table. The measures have been calculated using the actual financial statements, including IFRS 16.

	Jul - Sep 2026	Jul - Sep 2025	Jan - Sep 2026	Jan - Sep 2025	Oct 2025 - Sep 2026	Jan - Dec 2025
Gross margin (gross profit/net sales)						
Gross profit, SEK million	49.5	42.3	145.8	144.7	203.0	201.9
Net sales, SEK million	59.7	56.4	181.7	178.5	253.7	250.5
Gross margin, %	83.0	75.0	80.2	81.1	80.0	80.6
EBITDA margin (EBITDA/net sales)						
Operating profit/loss, SEK million[1]	7.1	1.3	10.2	-8.0	28.2	10.1
Depreciation/amortization, SEK million	-7.6	-6.8	-22.6	-20.1	-29.6	-27.1
Net sales, SEK million	59.7	56.4	181.7	178.5	253.7	250.5
EBITDA margin, %[1]	24.6	14.4	18.1	6.8	22.8	14.8
Operating margin (operating profit/net sales)						
Operating profit/loss, SEK million[1]	7.1	1.3	10.2	-8.0	28.2	10.1
Net sales, SEK million	59.7	56.4	181.7	178.5	253.7	250.5
Operating margin, %[1]	11.9	2.3	5.6	Neg	11.1	4.0
Return on equity (profit for the period/average equity)						
Profit/loss for the period, SEK million	7.3	-2.8	11.8	-22.0	25.4	-8.4
Average equity, SEK million	385.2	339.5	371.9	345.0	365.2	351.7
Return on equity, %	1.9	Neg	3.2	Neg	7.0	Neg
Equity ratio (closing equity for the period/closing total assets for the period)						
Closing equity, SEK million	389.4	341.0	389.4	341.0	389.4	354.3
Closing total assets, SEK million	495.0	459.9	495.0	459.9	495.0	469.7
Equity ratio, %	78.7	74.1	78.7	74.1	78.7	75.4
Growth adjusted for exchange rate changes (((sales in currency for the period * (previous period's average exchange rate - average exchange rate for the period in currency) + net sales)) - previous period's net sales)))/previous period's net sales)						
Net sales in EUR million	4.1	3.8	12.5	11.2	16.7	15.4
Net sales in USD million	1.2	0.4	4.8	2.9	7.0	5.2
Net sales in GBP million	0.2	0.1	0.4	0.4	0.6	0.6
Net sales, SEK million	59.7	56.4	181.7	178.5	253.7	250.5
Average exchange rate EUR/SEK	11.1011	11.1220	10.8974	11.1097	10.9112	11.0698
Average exchange rate USD/SEK	9.6478	9.5144	9.3876	9.9585	9.3930	9.8199
Average exchange rate GBP/SEK	12.9699	12.8299	12.6203	13.0644	12.5940	12.9258
Sales growth adjusted for exchange rate changes, %	5.7	19.2	4.9	20.4	8.9	20.2

1) Restated due to reclassified currency translation differences related to long-term intra-Group loans. See Note 1.

About Devyser

Devyser is redefining how laboratories approach genetic testing. We offer streamlined and user-friendly solutions for a wide range of conditions, helping labs overcome complexity, reduce turnaround times, and maximize efficiency.

Our technologies simplify workflows, minimize hands-on time, and deliver fast, accurate results. Every test is designed to empower labs to do more with less, freeing up resources while supporting better patient outcomes.

We specialize in diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories - two critical areas where accuracy and speed matter. With customers in 65+ countries, we also operate our own CLIA-certified laboratory, Devyser Genomic Laboratories, in Atlanta, and maintain sales offices across Europe and the US.

Devyser is committed to regulatory excellence under IVDR, ensuring the highest quality standards across our growing product portfolio.

Founded in 2004 and headquartered in Stockholm, Devyser is listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR).

For more information, visit www.devyser.com.

Contact details

Niklas Axelsson
CFO
Tel: +46 8 562 158 50
Email: ir@devyser.com

All reports are published on the company's website: https://investors.devyser.com/en/reports-presentations

Financial calendar

Interim report Q1 2026	April 27, 2026
Annual General Meeting 2026	May 6, 2026
Interim report Q2 2026	July 20, 2026
Interim report Q3 2026	November 3, 2026
Year-end report 2026	February 16, 2027

Analysts covering the Company

Arvid Necander, DNB Carnegie Investment Bank
Filip Wiberg, Pareto Securities

Devyser Diagnostics AB
Bränningevägen 12
120 54 Årsta, Sweden
www.devyser.com

Auditor’s report

To the Board of directors in Devyser Diagnostics AB (publ), corporate identity number 556669-7834

Introduction

We have conducted a limited review of the condensed interim financial information (interim report) for Devyser Diagnostics AB (publ) as of September 30, 2026, and the nine-month period ending on that date. The board of directors and the managing director are responsible for preparing and presenting this interim report in accordance with IAS 34 and the Swedish Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our limited review.

The focus and scope of the limited review

We have conducted our limited review in accordance with the International Standard on Review Engagements ISRE 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity." A limited review consists of making inquiries, primarily of persons responsible for financial and accounting matters, performing analytical procedures, and other review procedures. A limited review has a different focus and a significantly smaller scope compared to the focus and scope of an audit conducted in accordance with ISA and generally accepted auditing standards. The review procedures taken in a limited review do not enable us to obtain the assurance that we would become aware of all significant matters that might have been identified in an audit. Therefore, the conclusion expressed based on a limited review does not have the assurance that a conclusion expressed based on an audit has.

Conclusion

Based on our limited review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the group in accordance with IAS 34 and the Annual Accounts Act and for the parent company in accordance with the Annual Accounts Act.
Stockholm, 3 November 2026
Öhrlings PricewaterhouseCoopers AB

Magnus Lagerberg
Authorized Public Accountant

This is a translation of the Swedish language original. In the event of any differences between this translation and the Swedish language original, the latter shall prevail.